外泌体miRNA在肺癌诊疗中的研究进展  

Progress of exosomal miRNA in the diagnosis and treatment of lung cancer

作　　者：薛林燕慧 杨九龙 于新娟[2] 韩伟[2] 李双保[2] Xue Linyanhui;Yang Jiulong;Yu Xinjuan;Han Wei;Li Shuangbao(Clinical Medicine College,Weifang Medical University,Weifang 261053,China;The Second Department of Pulmonary and Critical Care Medicine,Qingdao Municipal Hospital,Qingdao 266071,China)

机构地区：[1]潍坊医学院临床医学院,261053 [2]青岛市市立医院呼吸与危重症医学二科,266071

出　　处：《国际呼吸杂志》2021年第5期391-395,共5页International Journal of Respiration

基　　金：国家自然科学基金(81973012)。

摘　　要：外泌体是一种几乎所有细胞都能分泌的胞外小泡,在细胞和器官之间运输脂质、蛋白质和核酸。作为一种天然细胞间通信器,外泌体广泛分布在生物体液中。外泌体中的微小RNA(miRNA)在肿瘤的发生、发展和侵袭转移中起至关重要的作用,并具有成为肿瘤生物标志物的潜力。本文综述了外泌体中miRNA在肺癌诊断、预后评估及药物疗效预测中的作用,并总结其面临的挑战。Exosomes are extracellular vesicles that can be secreted by almost all cells,transporting lipids,proteins and nucleic acids between cells and organs.As a natural intercellular communicator,exosomes are widely distributed in biological body fluids.MicroRNA(miRNA)in exosome play an important role in the occurrence,development,invasion and metastasis of tumor,and they have great potential as a non-invasive biomarker for tumor diagnosis.This article reviews the role of miRNA in exosome in the diagnosis,prognosis and drug efficacy prediction of lung cancer,and summarizes the challenges.

关 键 词：外泌体 微小RNA 肺癌 诊断 生物标志物 

分 类 号：R734.2[医药卫生—肿瘤]